Patients with chronic idiopathic urticaria (CIU) often remain symptomatic despite treatment with H1 antihistamines. 18,19 In 2014, XOLAIR became the only FDA-approved CIU treatment 22 for patients 12 years of age and older when antihistamines are not enough. Based on US data, XOLAIR has been prescribed for more than 150,000 appropriate CIU patients. 10

CIU Symptoms and Characteristics

CIU is a condition characterized by itch and hives that are idiopathic and last for 6 weeks or more. 18,19 Here are some common characteristics:

  • Women are twice as likely as men to experience CIU, 19 and the greatest incidence is seen between 20 and 40 years of age. 18
  • Hives appear suddenly and are usually recurrent; generally, individual hives last less than 24 hours, but new hives often develop simultaneously at different sites on the skin. 18,19

CIU Can Be an Ongoing Cycle

Even after finding a diagnosis, about 50% of CIU patients continue to experience itch and hives, despite H1 antihistamine treatment. 18,19
View the XOLAIR CIU clinical study results.

Who Might Be Appropriate for XOLAIR?

XOLAIR may be considered as a treatment option if your patients with CIU:

  • Are still experiencing recurrent itch and hives, despite H1 antihistamine treatment
  • Have had hives for 6 weeks or more that are idiopathic
  • Are ≥12 years

CIU Treatment: See What the Urticaria Guidelines Say

These evidence- and consensus-based guidelines were developed with the participation of 42 national and international societies, and are endorsed by AAAAI, ACAAI, and AAD. 26

AAAAI, American Academy of Allergy, Asthma, and Immunology; AAD, American Academy of Dermatology; ACAAI, American College of Allergy, Asthma, and Immunology; EAACI, European Academy of Allergy and Clinical Immunology; EDF, European Dermatology Forum; GA2LEN, Global Allergy and Asthma European Network; WAO, World Allergy Organization.

*In addition, a short course of glucocorticosteroids may be considered in the case of a severe exacerbation. Other treatment options are available; see Table 9 of Zuberbier et al. 2018.
A 4-times increase in the sgAH dose if not FDA approved.
Cyclosporine A is off label for urticaria.

In patients who remain symptomatic despite H1 antihistamines, consider XOLAIR.